128 related articles for article (PubMed ID: 7596181)
1. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Keating MJ
Leukemia; 1995 Jun; 9(6):943-5. PubMed ID: 7596181
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
4. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
Weiss M; Spiess T; Berman E; Kempin S
Leukemia; 1994 Aug; 8(8):1290-3. PubMed ID: 8057664
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
[TBL] [Abstract][Full Text] [Related]
6. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
7. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating MJ
Leukemia; 1995 Sep; 9(9):1444-9. PubMed ID: 7658710
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
15. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M
Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
17. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
[TBL] [Abstract][Full Text] [Related]
18. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
19. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]